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Background: The aim of this study was to evaluate the antimicrobial resistance and genetic 
basis for metronidazole (Mtz) and clarithromycin (Cla) resistance in strains of Helicobacter 
pylori, isolated from patients with gastroduodenal disorders.
Patients and methods: A total of 157 H. pylori isolates (from 22 gastric cancer, 38 peptic 
ulcer disease, and 97 non-ulcer dyspepsia patients) were analyzed for drug susceptibility to 
Mtz and Cla, by gradient diffusion test (E-test, MAST). The PCR and sequence analysis of the 
rdxA and frxA for Mtz-resistant strains and the 23S rRNA for Cla-resistant strains were used to 
determine the genetic basis of drug resistance in H. pylori strains. Increased expression of TolC 
homologous genes (hefA) that upregulates efflux pump activity was determined in multidrug-
resistant (MDR) strain of H. pylori by real-time PCR technique.
Results: Among 157 H. pylori isolates, 32 (20.4%) strains were resistant to at least one of the 
antimicrobial agents. The highest resistance rate was attributed to Mtz (n=69, 43.94%). Among 
the resistant strains of H. pylori, 15 cases (9.55%) were detected as MDR. Mutations in the 
rdxA (85.5%) and A2143G point mutations (63.1%) in the 23S rRNA were the most common 
cause of resistance to Mtz and Cla in strains of H. pylori, respectively. In MDR strains, the 
rdxA mutation and A2143G-point mutation in the 23S rRNA were the most abundant mutations 
responsible for drug resistance. The relative expression of hefA in MDR strains (mean 3.706) 
was higher than the susceptible strains (mean 1.07).
Conclusion: Mutational inactivation and efflux pump overexpression are two mechanisms that 
increase the resistance to H. pylori antimicrobial agents and the rate of MDR strains. In Iran, the 
mutations of rdxA and frxA in Mtz-resistant strains and A2143G and A2142G of the 23S rRNA 
in Cla-resistant strains were significant. The screening for these mutations could help to prevent 
antibiotic resistance, and to determine the most effective anti-H. pylori drugs.
Keywords: H. pylori, drug resistance, efflux pump, genetic mutations
Introduction
Helicobacter pylori is an etiological factor for gastroduodenal disorders such as chronic 
gastritis, peptic ulcer disease (PUD), and in more severe cases, H. pylori infection may 
result in gastric cancer (GC).1 Treatment of H. pylori infection is usually a challenge 
because the strains of H. pylori are susceptible to most antimicrobial agents in vitro, 
but in vivo the successful treatment is hard.2 Treatment process is usually performed 
by a combined therapy regimen that recommended eradicating the H. pylori infection. 
The emergence of antibiotic resistance is considered as the major cause of treatment 
failure.3,4 A successful combination therapy of a proton pump inhibitor and simulta-
neous prescription of two or three kinds of antibiotics, including tetracycline (Tet), 
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metronidazole (Mtz), clarithromycin (Cla), and amoxicillin 
(Amx) are recommended for treatment of H. pylori infec-
tion. The prevalence of antibiotic resistance of strains of H. 
pylori varies in different geographical regions, and is associ-
ated with the consumption of antibiotics in those areas.5 In 
recent years, the widespread use of antibiotics has increased 
the rate of resistance of H. pylori to standard therapies. 
Resistance to Mtz and Cla has increased worldwide, and also 
multidrug-resistant (MDR) strains of H. pylori and simulta-
neous resistant to Mtz, Cla, and Amx have been reported.6,7 
Recent studies suggest that the underlying antibiotic resis-
tance mechanisms are mainly due to the genetic plasticity of 
H. pylori that results in genetic mutations.7–9 These include 
point mutation, involving substitution of A to G at positions 
2142 and 2143, in the domain V of the 23S rRNA, which 
confers resistance toward Cla.9 Similarly, mutations in the 
rdxA and frxA are reported to confer Mtz resistance in H. 
pylori.9 Mutational patterns in the 23S rRNA, rdxA, and 
frxA are caused by the inactivation of the gene function via 
frameshift mutation, insertions, and deletions, and showed 
wide geographical divergence.
In addition, possible mechanisms of intrinsic drug 
resistance involve decreased drug uptake or increased drug 
efflux. Efflux of compounds is a phenomenon commonly 
observed in bacteria.8,10,11 Five families of multidrug efflux 
transporters have been described. One of them, widespread in 
Gram-negative bacteria, is the resistance-nodulation-division 
(RND) family of efflux systems.12–14 There are three RND 
families: hefABC, hefDEF, and hefGHI. The hefA, hefD, and 
hefG are the TolC homolog, encoding the outer membrane 
protein belonging to efflux pump. About 69% of the Iranian 
population were infected by H. pylori, and failure in treatment 
could be caused by the development of partial gastritis to 
PUD or GC.15 The aim of the present study was to investigate 
the frequency of drug resistance in H. pylori strains, and to 
employ the molecular methods for analysis of genes related 
to Mtz and Cla resistance. This study may have the potential 
to improve the prognosis and empiric treatment in Ahvaz, 
Iran, in a clinical setting.
Recent studies suggest that the underlying antibiotic 
resistance mechanisms are mainly due to the genetic plas-
ticity of H. pylori that result in genetic mutations. These 
include point mutation, involving substitution of A to G at 
positions 2142 and 2143, in the domain V of the 23S rRNA, 
which confers resistance toward Cla.8 Similarly, mutations 
in the rdxA and frxA are reported to confer Mtz resistance in 
H. pylori.9 Unlike mutational patterns in the 23S rRNA, the 
mutations in the rdxA and frxA are caused by the inactiva-




The study was approved by the Research Ethics Committee of 
the Ahvaz Jundishapur University of Medical Sciences (No: 
IR.AJUMS.REC.1395.220.), Ahvaz, Iran. Written informed 
consent was obtained from all the gastroduodenal patients.
Bacterial culture and Dna isolation
A total 157 H. pylori (22 GC, 38 PUD, and 97 non-ulcer 
dyspepsia [NUD]) strains originally isolated between 2015 
and 2016 from 150 patients living in Ahvaz, Khuzestan 
province, Iran, were selected. The patients who had not 
received nonsteroidal anti-inflammatory drugs or any anti-
Helicobacter therapy at least for 3 months prior to endoscopy 
were included. Upper gastro-endoscopy was performed on 
patients’ with clinical symptoms, including gastritis, abdomi-
nal pain, weight loss, epigastric pain, vomiting, dyspepsia 
and history of GC, melena, anemia, and history of gastric 
ulcer for biopsy collection. Brucella agar (EMD Millipore, 
Billerica, MA, USA), supplemented with 7% defibrinated 
sheep blood, 7% fetal calf serum (FCS), 10 mg/L vancomy-
cin, 5 mg/L amphotericin B, 5 mg/L trimethoprim, and 20 
U/mL polymyxin B, was used to culture the H. pylori strains 




, and 85% 
N
2
; EMD Millipore) for 5–7 days, and all the plates were 
incubated at 37°C with 100% humidity. Based on colony 
morphology (small and translucent colonies), bacterial shape 
(curved), and a Gram-negative stain, and also using biochemi-
cal tests, including urease, catalase, and oxidase, preliminary 
detection of H. pylori was performed. After sub-culturing a 
colony (twice or thrice) on the Brucella agar, supplemented 
with 7% sheep blood, all the isolates were stored in skim 
milk with 20% glycerol and 7% FCS at −70°C.16,17 Genomic 
DNA was extracted from antral biopsy and the colonies 
using the high pure DNA extraction kit (Hoffman-La Roche 
Ltd., Basel, Switzerland), according to the manufacturer’s 
instruction. Then, the extracted DNA was quantified, using 
a biophotometer through measurement of the associated OD 
at 260 nm (Eppendorf, Hamburg, Germany).
Detection of H. pylori by PcR assay
For preliminary detection of H. pylori strains, the PCR 
assay was performed using the primers based on the H. 
pylori 16S rDNA.18 PCR assays were performed using one 
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GAAGGCGA-3′), amplifying a 150-bp fragment.19 PCR 
assay was carried out in a thermocycler nexus gradient 
(Eppendorf). A 25 µL final reaction, including 10× PCR 
buffer, 1.5 mM MgCl
2
, 10 mM dNTPs, 0.5 µM of each 
primer, 1.5 U super Taq polymerase, and 5 µL of template 
DNA was prepared for PCR assay. The cycling parameters 
were 40 cycles of 95°C for 5 minutes, 56°C for 1 minute, 
and 72°C for 1 minute. The amplified products were detected 
by electrophoresis on a 2% agarose gel containing ethidium 
bromide (500 ng/mL). The bands were visualized using A10 
system (Bio-Rad Laboratories Inc., Hercules, CA, USA).
antibiotic susceptibility testing
Bacterial colonies obtained during 72-hour culture were sus-
pended in the brain heart infusion broth with a density of three 
on the McFarland scale, 108 cells CFU/mL. In the next stages, 
the bacterial suspension was inoculated on Mueller-Hinton 
medium (Becton Dickinson, Franklin Lakes, NJ, USA), 
supplemented with 10% defibrinated sheep blood. Then 
E-test antibiotic impregnated with a gradient of concentration 
was imposed to determine the value of minimum inhibitory 
concentration (MIC) for the growth of bacteria. Plates were 
then incubated at 37°C for 72 hours under microaerophilic 
conditions. Criteria for interpretation of results were MIC 
(µg/mL) for resistant strains: Amx ≥2, Cla ≥1, Mtz ≥8, Tet ≥4, 
and ciprofloxacin (Cip) ≥1. H. pylori strain ATCC43504 was 
used as a reference strain for the quality control of antibiotic 
susceptibility testing.20–23
Molecular detection on H. pylori-resistant 
strains
The PCR-based sequencing was used for genetic analysis of 
antibiotic-resistant strains. Genes related to drug resistance, 
including the rdxA, frxA, and 23S rRNA were amplified by 
PCR using specific primers as previously described.9,24,25 The 
PCR products were separated using a 2% agarose gel stained 
by safe stain and visualized under UV light. Target band 
was extracted by the GF-1 Gel DNA Recovery Kit (Vivantis 
Technologies Sdn. Bhd., Selangor Darul Ehsan, Malaysia).
sequence data analysis
The target PCR products belonging to the rdxA, frxA, and 23S 
rRNA in 157 strains of H. pylori isolated from GC, PUD, and 
NUD patients were collected and sent for sequence analysis 
to the Bioneer Corporation, Daejeon, South Korea. Com-
parative sequence analysis between resistant and sensitive 
strains was performed by MEGA version 6 software.26 H. 
pylori 26695 (GenBank accession number NC_000915.1; 
GI: 15644634) was used as a reference genome for alignment 
of sequence data.
The hefA expression in MDR and the 
reference strain by real-time (RT)-PcR 
assay
Total Rna extraction
Fifteen isolates of MDR strains of H. pylori were cultured 
on Mueller-Hinton agar, supplemented with 5% defibrinated 
sheep blood, 7% FCS, 1, 2, and 8 µg/mL of Cla, Amx, 
and Mtz, respectively. All plates were incubated at 37°C, 
under microaerophilic conditions. Bacterial suspension 
was prepared in normal saline. The cells were then isolated 
by centrifugation (9,000×g for 10 minutes), and the pellet 
was used for total RNA extraction. RNA in MDR strains 
was isolated using the RNA extraction kit (Hoffman-La 
Roche Ltd.) and then reverse transcribed into cDNA. The 
hefA vs gyrB (an endogenous gene) was used to study the 
relative expression of the hefA in 15 MDR clinical strains 
and strain ST7136 of H. pylori. cDNA of hefA and gyrB 
was amplified using RT-PCR (ABI StepOne™; Thermo 
Fisher Scientific, Waltham, MA, USA) in the presence of 
Real Master Mix (SYBR Green; TaKaRa, Shiga, Japan). 
The sequences of hefA (GenBank, accession number 
AF059041), including F: (5′-CTCGCTCGCATGATCGC-3 
and R: (5′-CGTATTCGCTCAAA-TTCCCT-3′) were used 
to amplify a 162-bp fragment. The expression of the house-
keeping gene (GenBank, accession number AB084049) 
was assessed in parallel with the primer pair gyrB: F: 
(5′-TTACTACGACTTATCCTGGGGCTAGCGCTG-3′) 
and R: (5′-CCCCATCAAT-TTCCACATTCTCCGC-3′), 
amplifying a 267-bp fragment. Then, the hefA expression 
in MDR and susceptible strain were determined.27
Results
assessment of susceptibilities to 
antimicrobial agents in clinical strains
The MIC of Mtz and Cla was determined for 157 strains of 
H. pylori. Both biopsy samples and colonies were confirmed 
by PCR analysis in 22 GC, 38 PUD, and 97 NUD patients 
by gradient diffusion test. In general, among 157 isolates 
of H. pylori, 32 (20.4%) strains were resistant to only one 
of the antimicrobial agents (Table 1). Single resistance was 
observed only in Mtz or Cip. The highest resistance rate 
was attributed to Mtz (n=69, 43.94%). The frequency of 
double and MDR phenotypes is listed in Table 2. Among the 
resistant strains, MDR strains were detected in 3 (13.6%), 5 
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genetic variations of the rdxA and frxA in 
Mtz-resistant strains
The sequences of the rdxA and frxA were analyzed in 57 Mtz-
resistant and 5 Mtz-sensitive strains of H. pylori (Figure 1). 
Sequences of the rdxA and frxA in sensitive strains were 
pairwise aligned with a reference strain by MEGA version 5 
software, showing 95.6%–97.1% and 97.3%–98.7% identity 
in both genes, respectively. Alteration in amino acid sequences 
of the rdxA was detected in 50/57 (87.7%) Mtz-resistant 
strains. Out of 50 strains, 28 (49.1%) translational frameshifts 
were caused by the presence of premature stop codon through 
substitution of amino acid in the truncated rdxA (Table 3). The 
rdxA mutations, including missense and nucleotide insertion/
deletion were detected in 8 (14%) and 14 (24.6%), respec-
tively, in the Mtz-resistant strains. In addition, the premature 
stop codon (29.8%) was seen as the most common mutation 
in the frxA in Mtz-resistant strains (Table 3). In the MDR 
strain, the truncated rdxA and frxA were detected as the most 
common mutation responsible for Mtz resistance (Table 4).
genetic variations of the 23S rRNA in 
cla-resistant strains
The V domain of 23S rRNA was sequenced in the 38 Cla-
resistant strains and compared to the reference genome of 
H. pylori 26695 exhibiting two-point mutations, including sub-
stitution of a single nucleotide A2143G (63.1%) and A2142G 
(34.2%) in 24 and 13 strains, respectively (Figure 1). Simulta-
neous double mutations of the A2143G and A2142G have not 
been found in these strains. The A2142C, A2144T, C2245T, 
G2141A, and G2224A were among the other mutations that 
have been found in Cla-resistant strains of H. pylori (Table 3).
Expression of efflux pump hefa gene in 
MDR strains
The expression of hefA and gyrB in MDR and susceptible 
strain was assessed by RT-PCR assay. Each relative expres-
sion value was the mean of three replicates. In 15 clinical 
isolates, the relative expression of hefA vs gyrB in MDR 
strains of H. pylori (mean 3.706) was higher than the seven 
susceptible strains (mean 1.07) (Table 5).
Discussion
In Iran, like other developing countries, H. pylori has infected 
the majority of the adult population. According to serology 
data, the incidence of H. pylori infection in Iranian adults 
is up to 80%.28 In the present study, resistance to Mtz, Cla, 
Tet, Amx, and Cip were determined in strains of H. pylori 
by gradient diffusion test (E-test, MAST). Single resistance 
Table 1 Prevalence of antimicrobial resistance in clinical Helicobacter pylori isolates
Antibiotic MIC in resistant strain (µg/mL) GC (22), n (%) PUD (38), n (%) NUD (97), n (%) Total, n (%) P-value
Mtz ≥8.0 12 (54.5) 15 (39.5) 42 (43.3) 69 (43.9) 0.542
cla ≥1.0 7 (31.8) 8 (21) 23 (23.7) 38 (24.2) 0.118
amx ≥2.0 4 (18.2) 6 (15.8) 13 (13.4) 23 (14.6) 0.321
Tet ≥4.0 6 (27.3) 7 (18.4) 19 (19.6) 32 (20.4) 0.177
cip ≥1.0 5 (22.7) 6 (15.8) 23 (23.7) 34 (21.7) 0.215
Abbreviations: Amx, amoxicillin; Cip, ciprofloxacin; Cla, clarithromycin; GC, gastric cancer; MIC, minimum inhibitory concentration; Mtz, metronidazole; NUD, non-ulcer 
dyspepsia; PUD, peptic ulcer disease; Tet, tetracycline.
Table 2 Primary and combined resistance of Helicobacter pylori isolates to antimicrobial agents
Antibiotic phenotypes 
(single, double, triple, and 
quadruple drug resistance)









Mtz 4 (18.2) 6 (15.8) 17 (14.4) 27 (17.2)
cip – 2 (5.3) 3 (3.1) 5 (3.2)
Mtz + cla + amx + Tet 3 (13.6) 5 (13.2) 7 (7.2) 15 (9.6)
Mtz + cla + Tet + cip 2 (9.1) 1 (2.6) 6 (6.2) 9 (5.7)
cla + amx + Tet + cip 1 (4.5) 1 (2.6) 6 (6.2) 8 (5.1)
Mtz + cla 1 (4.5) 1 (2.6) 4 (7.2) 6 (3.8)
Mtz + cip 2 (9.1) 2 (5.3) 8 (8.2) 12 (7.6)
Total resistant 13 (59.1) 18 (47.4) 51 (52.6) 82 (52.2)
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was observed only in two antibiotics; Mtz (17.2%) and Cip 
(3.2%), while double resistance and MDR were seen in 11.5% 
and 20.4%, respectively. Among 157 H. pylori isolates, 82 
(52.2%) cases were resistant to at least one antibiotic, and the 
highest resistance rate was attributed to Mtz (n=69, 43.9%). 
The prevalence of resistance to Mtz in strains of H. pylori in 
Iran is high; the prescription of Mtz as a common anti-parasite 
drug and as a drug for gynecological disorders could be the 
cause of the high level of resistance in strains of H. pylori.29–32 
In addition, in the mini-review article published by Khademi 
et al3 in Iran, drug resistance data from different strains of 
H. pylori were collected from different parts of Iran, and the 
prevalence of Mtz resistance was reported as 61.6%.30
In the literature, limited information exists regarding 
the mechanism of resistance to Mtz in H. pylori and has 
not yet been clearly understood. However, some factors that 
might be relevant to the mechanism of Mtz resistance are as 
follows: 1) overexpression of TolC homologous genes that 
upregulates efflux pump activity and reduces activity of nitro-
reductases and 2) mutational inactivation of the rdxA and/or 
frxA encoding an oxygen-insensitive NADPH nitroreductase 
and NAD(P)H flavin oxidoreductase, respectively.32,33 These 
mutations, without leading to death, could be the cause of 
drug resistance during the clinical application.34 Therefore, 
in agreement with previous studies we have confirmed that 
Mtz should not be the choice for the first line H. pylori 
eradication therapy.35,36
In the present study, among Mtz-resistant strains, 63 
(92.7%) cases possessed mutation in one or both of the 
rdxA and frxA, and the most common mutations were due to 
a premature stop codon (substitution of single amino acid) 
in the rdxA (40.6%) and frxA (24.6%), while 8.2% of Mtz-
resistant strains did not contain any alteration in any of the 
rdxA and frxA. In the study conducted by Abdollahi et al in 
Iran, among 35 resistant H. pylori isolates only 22.9% (8/35 
isolates) deletion mutations were detected in the rdxA, while 
in the study performed by Teh et al,25 89.1% of Mtz-resistant 
strains possessed a premature termination codon or insertion/
deletion at one or both of the rdxA and frxA.25,37 Therefore, 
screening for alteration in the rdxA and frxA could be appro-
priate to identify about 92% of Mtz-resistant strains of H. 
pylori in the local population.
Resistance to Cla is contributed to the failure of H. pylori 
eradication in developing countries.30 In the present study, 
the Cla resistance was detected in 24.2% (38/157) of isolates, 
and was much lower than the resistance to Mtz. In the mini-
review article that was published by Khademi et al,3 the Cla 
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isolates, while the low resistance to Cla was reported from 
neighboring Asian countries, including Egypt (4%), Israel 
(8.2%), Saudi Arabia (4%), and Kuwait (0%).30,38,39 Therefore, 
the rate of Cla-resistant strains of H. pylori, in Iran is higher 
than in the Middle East and developed countries. The three 
most frequent point mutations, the A2143G, A2142G, and 
A2142C in the 23S rRNA component of ribosomes were 
related to Cla resistances in H. pylori.40–42 In the present 
study, the obtained sequences were aligned with the refer-
ence strain 26695 of H. pylori, and out of 38 Cla-resistant 
strains, 37 (97.3%) cases had mutations, such as the A2143G 
and A2142G. The A2143G (63.1%) was the most common 
point mutation in the 23S rRNA, followed by 34.2% of the 
A2142G substitution. There was no point mutation in the 
sensitive strains of H. pylori. Other mutations that have 
been observed in Cla-resistant H. pylori isolates were the 
A2142C and G2141A, G2224A, G2144T, and C2245T. 
Therefore, Cla-resistant strains could be detected in 97.3% 
(37/38) of the local population, by screening for mutations 
in conserved V domain of genes, encoding the 23S rRNA. In 
the study conducted by Teh et al,25 V domain of the 23S rRNA 
was sequenced in 14 Cla-resistant strains, and by screening 
for the A2142G or A2143G mutations of the 23S rRNA, 
they were able to detect 92.9% of Cla-resistant strains in the 
Malaysian population.25
The uncontrolled use of antibiotics may have led to the 
emergence of MDR strains of H. pylori. In the present study, 
MDR strains were detected in 9.6% (15/157) of H. pylori iso-
lates. The truncated rdxA (caused by premature stop codon) 
and deletion/insertion were detected as the most common 
mutational inactivation in the rdxA and frxA. Double point 
mutations were only detected in two MDR strains, includ-
ing the ST3204: A2143G, G2224A and ST3188: A2143G, 
Table 5 Relative expression of hefA gene vs gyrB in MDR clinical 
strains compared to susceptible strain
Strain Sequence type hefA/gyrA
























Abbreviation: MDR, multidrug resistant.
Table 4 Mutation patterns of Mtz- and cla-resistant strains in MDR Helicobacter pylori strains
MDR 
strain
MIC (µg/mL) Mutation 
description in Cla
Mutation description in Mtz
Cla Mtz 23S rRNA frxA rdxA
sT3175 32 64 a2143g Premature stop codon at arg86 Premature stop codon at gln11
sT3179 4 32 a2142g Premature stop codon at gln5 –
sT3177 8 256 a2143g Deletion of 3 nt (38–40) Premature stop codon at lys190
sT3188 16 256 a2143g, c2245T Premature stop codon at Met66 Deletion of 3 nt (38–40)
sT3182 32 64 a2142g – M56V
sT3187 8 128 a2143g l62V Deletion of 3 nt 163–165)
sT3183 4 32 a2143g – V32a
sT3188 8 16 a2142g Deletion of 3 nt (84–86) Premature stop codon at gln50
sT3191 32 64 a2142g Premature stop codon at Trp137 –
sT3196 32 32 a2143g Deletion of 2 nt (83–84) Insertion of 3 nt (80–82)
sT3201 8 32 a2142g – Premature stop codon at arg16
sT3203 4 128 a2143g, g2224a Insertion of 1 nt (72) Deletion of 3 nt (151–153)
sT3204 16 32 a2143g Premature stop codon at Tyr60 s111l
sT3205 8 64 a2142c – Premature stop codon at gly189
sT3194 32 128 a2143g – Deletion of 4 nt (81–84)
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Figure 1 Distribution of included patients and genetic mutations related with Mtz and cla resistance in Helicobacter pylori strains isolated from gastroduodenal disorders.
Notes: (A) Prevalence of gastroduodenal disorders in males and females. Mutations in rdxA, frxA, and 23S rRNA in (B) gc, (C) PUD, and (D) nUD.
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C2245T. Overall, no correlation was found between levels 
of MIC between Cla resistance and the point mutation in 
MDR strains.
Our findings suggested that the efflux pump system was 
overexpressed in the MDR strains of H. pylori, suggesting 
that the long-term and inappropriate administration of anti-
biotics in the clinic may be responsible for the appearance of 
these strains. Chromosomally encoded drug resistances in H. 
pylori via overexpression of the efflux pump systems were 
associated with MDR to antibiotics.43–45 In the present study, 
based on RT-PCR, our findings suggested that the efflux 
pump hefA were overexpressed in the MDR strains of H. 
pylori. The relative gene expression of hefA vs gyrB in 80% 
(12/15) of clinical MDR strains of H. pylori was significantly 
higher (P<0.05) in comparison to five susceptible strains. In 
general, antimicrobial susceptibilities of the isolates collected 
from GC, PUD, and NUD patients were compared, and no 
significant difference (P>0.05) in antimicrobial resistance 
was observed among these groups.
In spite of these observations, a major limitation of this 
study is the genome diversity of H. pylori. The main cause 
of resistance to Mtz and Cla is point mutations, which could 
influence efflux pump-related antibiotic resistance patterns. 
Therefore, it is difficult to distinguish between these two 
antibiotic resistance mechanisms. In conclusion, H. pylori 
genome evolves and shows wide geographical divergence. The 
prevalence of resistance to H. pylori antimicrobial agent is 
rapidly growing in Iran, and MDR strains have recently been 
reported. Mutational inactivation and the overexpression of 
efflux pump are two mechanisms that increase the resistance 
to H. pylori antimicrobial agents and the rate of MDR strains. 
In Iran, the mutations of rdxA and frxA in Mtz-resistant strains 
and the A2143G and A2142G mutations of 23S rRNA in 
Cla-resistant strains were significant, and screening for these 
mutations could help to determine the most effective anti-H. 
pylori drugs and to prevent antibiotic resistance.
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